Psyence Biomedical Ltd.
13F holders, Q2 2024 (June 30)10holders
2new positions
2sold out
$0.31avg. 13F price*
At the end of Q2 2024, 10 institutions reported holding Psyence Biomedical Ltd. in their 13F filings, unchanged from Q1 2024. 2 opened new positions and 2 sold out. The largest holders were AdvisorShares Investments LLC ($148K), Cantor Fitzgerald, L. P. ($101K) and UBS Group AG ($7K).
- Company
- Psyence Biomedical Ltd.
- CUSIP
- 74449F100
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $12K |
| Exits | 2 | $92K |
All 13F filers, Q1 2024 → Q2 2024: 257,693 shares bought and 92,367 shares sold, net +165,326 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| AdvisorShares Investments LLC | 0.03% | Add +70.7% | 463,042 | $148K |
| Cantor Fitzgerald, L. P. | 0.02% | No change | 337,000 | $101K |
| UBS Group AG | 0.00% | Add +868.1% | 22,885 | $7K |
| Clear Street LLC | 0.00% | New | 20,000 | $6K |
| Morgan Stanley | 0.00% | New | 20,000 | $6K |
| HRT Financial LP | 0.00% | Add +43.3% | 18,077 | $5K |
| Virtu Financial LLC | 0.00% | Reduce -43.6% | 14,899 | $4K |
| Geode Capital Management, LLC | 0.00% | No change | 10,488 | $3K |
| Headlands Technologies LLC | 0.00% | Reduce -74.0% | 25 | $8 |
| JPMorgan Chase & Co. | 0.00% | No change | 2 | $1 |
"% of holder's portfolio" is PSYENCE BIOMEDICAL LTD's weight in each manager's 13F, not the share of Psyence Biomedical Ltd. the manager owns.